Mimetic Innate Immune Cell Production Without CD34+ Enrichment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating innate immune cells, such as γδ T cells and NK cells, face challenges in standardized, large-scale production due to variable starting materials, complex logistics, and the need for donor cell selection, which limits their applicability and scalability.
Innovation Solution
A method involving the expansion of peripheral blood cells with amino-bisphosphonate and IL-2, reprogramming to iPSCs, and co-culturing with stromal cell lines deficient in M-CSF and expressing DLL1 in specific cytokines to generate γδ NKT cells, bypassing the need for CD34+ cell enrichment and spin EB formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If donor blood cells are used to generate innate immune cells, then cell production can be achieved, but standardized and large-scale production is challenging due to variable starting materials and complicated logistics
Solution Approach 1:
The invention changes the starting material parameter from donor blood cells to human pluripotent stem cells (hPSCs), which can be expanded indefinitely in culture. This parameter change enables standardized, large-scale production because hPSCs provide a uniform, renewable cell source that eliminates the variability and logistical complexity associated with collecting and processing donor blood cells from multiple individuals.
2Reliability
If CD34+ cell enrichment and spin EB formation are performed, then NK cell differentiation can be achieved, but the process becomes time-consuming and complex for industrial manufacturing
Solution Approach 1:
The invention extracts and eliminates the time-consuming and complex steps of CD34+ cell enrichment and spin embryoid body (EB) formation from the differentiation protocol. By using hPSCs that can be directly differentiated through simplified culture conditions with specific cytokines and stromal cell co-culture, the method achieves reliable NK cell differentiation without these intermediate steps, significantly reducing production time and simplifying the process for industrial manufacturing.
3Reliability
If KIR-HLA matching is performed to enhance NK cell cytotoxicity, then anti-cancer efficacy is improved, but donor selection becomes complex and limits the number of treatable patients
Solution Approach 1:
The invention creates universal NK cell products from hPSCs that can treat multiple patients without requiring individualized KIR-HLA matching. By deriving NK cells from pluripotent stem cells rather than donor blood cells, the method produces cells with reduced or absent KIR expression, making them universally applicable to patients with various HLA types. This universality eliminates the complex donor selection process while maintaining anti-cancer efficacy.
Data Source
Figure 1a~1l
Figure 2a~2e
Figure 2f
AI summary
Human pluripotent stem cells (hPSCs), especially induced pluripotent stem cells (iPSCs) provide a promising starting material to produce mimetic innate immune cells such as natural killer (NK) cells and γδ T-cells for cancer immunotherapy. To facilitate consistent mass production, an overall manufacturing scheme to make mimetic innate immune cells from hPSCs was designed and demonstrated. Particularly, a robust protocol to differentiate hPSCs into NK cells or γδ T-cells through sequential hematopoietic differentiation on stromal cell line deficient in expressing M-CSF and lymphoid commitment on stromal cell line deficient in expressing M-CSF ectopically expressing DLL1 without employing CD34+ cell enrichment and spin embryoid body formation is established. Using this two-stage protocol, the generation of functional mimetic NK cells and functional mimetic γδ NKT-cells was demonstrated from hPSCs, including hESCs, peripheral blood cell-derived iPSCs (PBC-iPSCs), non-T cell-derived iPSCs or γδ T cell-derived iPSCs and the use of these mimetic innate immune cells in killing cancer cells.